Novus Biologicals products are now on bio-techne.com

Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein, CF

Images

 
There are currently no images for VEGFR2/KDR/Flk-1 (443-KD/CF).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity MuSpecies Glossary
Applications Bioactivity
Format
Carrier-Free

Order Details

Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-30 ng/mL in the presence of 5 ng/mL recombinant mouse VEGF.
Source
Mouse myeloma cell line, NS0-derived mouse VEGFR2/KDR/Flk-1 protein
Mouse VEGFR2
(Ala20-Glu762)
Accession # P35918
IEGRMD Human IgG1
(Pro100-Lys330)
6-His tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Ala20
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
Kdr
Purity
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity
Theoretical MW
110 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
166-191 kDa, reducing conditions
Publications
Read Publications using
443-KD/CF in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS.
Purity
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein, CF

  • CD309 antigen
  • CD309
  • EC 2.7.10
  • EC 2.7.10.1
  • Fetal liver kinase 1
  • fetal liver kinase-1
  • Flk1
  • Flk-1
  • FLK1tyrosine kinase growth factor receptor
  • KDR
  • kinase insert domain receptor (a type III receptor tyrosine kinase)
  • Kinase insert domain receptor
  • KRD1
  • Ly73
  • Protein-tyrosine kinase receptor flk-1
  • soluble VEGFR2
  • vascular endothelial growth factor receptor 2
  • VEGF R2
  • VEGFR
  • VEGFR2
  • VEGFR-2

Background

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

Mouse VEGFR2 cDNA encodes a 1367 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 743 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 583 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2 Fc Chimera binds VEGF with high affinity and is a potent VEGF antagonist.

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
  2. Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA. 95:548.

Customers Who Viewed This Item Also Viewed...

DVE00
Species: Hu
Applications: ELISA
AF321
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
AF231
Species: Hu
Applications: CyTOF-ready, Dual ISH-IHC, ELISA(Cap), ELISA(Det), ELISA(Sta), Flow, ICC, IHC, IP, Simple Western, WB
AF4117
Species: Rt
Applications: IHC, WB
AF743
Species: Mu
Applications: CyTOF-ready, Flow, WB
AF3628
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, WB
AF887
Species: Hu, Mu, Rt
Applications: CyTOF-ready, IHC, ICFlow, Simple Western, WB
NB110-41083
Species: Hu
Applications: ChIP, ELISA, ICC/IF, WB
AF1356
Species: Hu, Mu
Applications: CyTOF-ready, Dual ISH-IHC, Flow, IHC, Simple Western, WB
DPG00
Species: Hu
Applications: ELISA
AF566
Species: Mu, Rt
Applications: Block, CyTOF-ready, Flow, IHC, WB
NBP2-22203
Species: Hu, Pm, Mu, Rt
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
DVEC00
Species: Hu
Applications: ELISA
233-FB
Species: Hu
Applications: BA
AF1042
Species: Mu
Applications: Dual ISH-IHC, IHC, WB
443-KD/CF
Species: Mu
Applications: Bioactivity

Publications for VEGFR2/KDR/Flk-1 (443-KD/CF)(10)

We have publications tested in 3 confirmed species: Human, Mouse, Llama.

We have publications tested in 6 applications: Binding Assay, Bioassay, Flow Cytometry, In Vivo, Surface Plasmon Resonance, Western Blot.


Filter By Application
Binding Assay
(1)
Bioassay
(4)
Flow Cytometry
(1)
In Vivo
(1)
Surface Plasmon Resonance
(1)
Western Blot
(2)
All Applications
Filter By Species
Human
(2)
Mouse
(4)
Llama
(1)
All Species
Showing Publications 1 - 10 of 10.
Publications using 443-KD/CF Applications Species
V Mashayekhi, KT Xenaki, PMP van Bergen, S Oliveira Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy Cancers, 2020-09-23;12(10):. 2020-09-23 [PMID: 32977602] (Bioassay, Llama) Bioassay Llama
K Fujiwara, A Tsunei, H Kusabuka, E Ogaki, M Tachibana, N Okada Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold Cells, 2020-05-09;9(5):. 2020-05-09 [PMID: 32397414] (Flow Cytometry, Mouse) Flow Cytometry Mouse
T Ikeuchi, S de Vega, P Forcinito, AD Doyle, J Amaral, IR Rodriguez, E Arikawa-Hi, Y Yamada Extracellular Protein Fibulin-7 and Its C-Terminal Fragment Have In Vivo Antiangiogenic Activity Sci Rep, 2018-12-05;8(1):17654. 2018-12-05 [PMID: 30518776] (Bioassay, Human) Bioassay Human
Naoki Okada Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research Mol Ther Oncolytics, 2016-11-16;3(0):16024. 2016-11-16 [PMID: 27909701] (Bioassay, Mouse) Bioassay Mouse
Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, Stahl S, Lofblom J Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep, 2014-12-17;4(0):7518. 2014-12-17 [PMID: 25515662] (Bioassay) Bioassay
Wuest TR, Carr DJ VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J. Exp. Med., 2009-12-21;207(1):101-15, S1-2. 2009-12-21 [PMID: 20026662] (In Vivo, Mouse) In Vivo Mouse
Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J. Biol. Chem., 2008-10-15;283(49):34250-9. 2008-10-15 [PMID: 18922791] (Binding Assay, Mouse) Binding Assay Mouse
Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem. Biol., 2006-05-01;13(5):549-56. 2006-05-01 [PMID: 16720276] (Surface Plasmon Resonance, Human) Surface Plasmon Resonance Human
Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschluter M, Strehl J, Rabe C, Sauerbruch T, Prieto J, Caselmann WH, Qian C Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther., 2006-04-13;13(16):1198-205. 2006-04-13 [PMID: 16617302] (Western Blot) Western Blot
Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J, Qian C, Caselmann WH, Schmitz V Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology, 2005-06-01;41(6):1233-40. 2005-06-01 [PMID: 15915456] (Western Blot) Western Blot

Reviews for VEGFR2/KDR/Flk-1 (443-KD/CF) (0)

There are no reviews for VEGFR2/KDR/Flk-1 (443-KD/CF). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for VEGFR2/KDR/Flk-1 (443-KD/CF) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional VEGFR2/KDR/Flk-1 Products

Blogs on VEGFR2/KDR/Flk-1

There are no specific blogs for VEGFR2/KDR/Flk-1, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein, CF and receive a gift card or discount.

Bioinformatics

Gene Symbol Kdr
Uniprot